An exploratory pharmacogenetic investigation evaluating patients receiving tenofovir prodrugs has identified multiple associations between specific single nucleotide polymorphisms and routine clinical laboratory markers of hepatic and renal function. Researchers examining individuals undergoing antiretroviral therapy for human immunodeficiency virus type 1 observed that while several genetic variants correlated with changes in hepatic enzymes and renal biomarkers, many of the detected associations were demonstrable only within the comprehensive combined regimen group. This distribution pattern created difficulty in distinguishing the genetic effects attributable specifically to tenofovir alafenamide fumarate from those related to tenofovir disoproxil fumarate.
The study cohort comprised fifty-four adult patients receiving specialized care through the East Tennessee State University Center of Excellence for HIV and AIDS Care. The enrolled population was predominantly male, accounting for 83.3 percent of the cohort, with an overall median age of 53.0 years and an interquartile range extending from 46.0 to 59.0 years. Participants were primarily non-Hispanic Caucasian individuals with a mean body mass index of 27.12 plus or minus 5.96 kilograms per square meter. Treatment classifications divided the participants based on the specific nucleoside reverse transcriptase inhibitor prodrug incorporated into their regimen, with twenty-five individuals assigned to tenofovir alafenamide fumarate and twenty-nine assigned to tenofovir disoproxil fumarate.
This investigation served as a defined substudy utilizing observational data collected from an earlier protocol focused on the tolerability and drug exposure of integrase strand transfer inhibitors. Patient health histories and laboratory parameters were compiled through electronic health records, capturing both baseline measurements near the initiation of therapy and the most recent clinical values available relative to study sampling. The laboratory outcomes evaluated included hepatic markers—alkaline phosphatase, alanine aminotransferase, and aspartate aminotransferase—alongside renal metrics consisting of blood urea nitrogen and estimated glomerular filtration rate derived using the 2009 Chronic Kidney Disease Epidemiology Collaboration equation.
Genomic testing was carried out using the Sequenom iPLEX ADME PGx Pro Panel v1.0 to analyze single nucleotide polymorphisms associated with drug absorption, distribution, metabolism, and excretion. Deoxyribonucleic acid was extracted from whole blood specimens, and genotype call rates were determined with dedicated MassARRAY software. Following the exclusion of three specific variants that exhibited low yield—rs5030865 at 77.7 percent, rs28371706 at 57.4 percent, and rs1065411 at 83.0 percent—the overall genotyping efficiency exceeded 95 percent. Out of 175 single nucleotide polymorphisms included on the commercial panel, 87 exhibited polymorphism across the patient specimens analyzed.
Statistical evaluation applied an additive genetic association model using multiple linear regression, designating the major allele as the reference and adjusting for age, sex, body mass index, baseline clinical values, and regimen grouping in the combined cohort. Continuous variable comparisons between the treatment groups were conducted using one-way analysis of variance. Owing to the explicitly exploratory pilot nature of the study, the investigators did not perform statistical power calculations or adjustments for multiple testing, establishing an alpha threshold of 0.05 to identify statistically significant associations.
Analysis of hepatic enzymes demonstrated that mean serum concentrations remained within established reference intervals across all patient groups, with no statistically significant differences between the two prodrug cohorts. Mean alkaline phosphatase measured 81.30 plus or minus 50.14 units per liter in the comprehensive cohort, 67.08 plus or minus 19.23 units per liter with tenofovir alafenamide fumarate, and 93.55 plus or minus 64.08 units per liter with tenofovir disoproxil fumarate, yielding a comparison p-value of 0.052. Six genetic variants associated significantly with alkaline phosphatase in the comprehensive group, including two variants on the VKORC1 gene—rs9923231 and rs9934438—that demonstrated complete linkage disequilibrium with an r-squared value of 1. Five significant associations were noted within the tenofovir alafenamide fumarate group, and three positive associations emerged in the tenofovir disoproxil fumarate group.
Alanine aminotransferase and aspartate aminotransferase levels similarly presented mean values situated comfortably within standard clinical boundaries. Across all regimens, mean alanine aminotransferase was 28.13 plus or minus 20.29 units per liter, showing no significant difference between the prodrug groups at a p-value of 0.171. Five single nucleotide polymorphisms associated with alanine aminotransferase in the comprehensive group, three of which were located at distinct positions on the VKORC1 gene. Mean aspartate aminotransferase values averaged 25.00 plus or minus 19.67 units per liter across the cohort, with no significant difference between treatment arms at a p-value of 0.264. Five variants associated with aspartate aminotransferase in the overall group, while the tenofovir disoproxil fumarate cohort displayed five positive associations and the tenofovir alafenamide fumarate group displayed one.
Five single nucleotide polymorphisms demonstrated associations in the comprehensive group, including two characterized by negative regression coefficients. The tenofovir alafenamide fumarate group yielded six variant associations with blood urea nitrogen, three of which were situated within the ABCB1 gene, whereas the tenofovir disoproxil fumarate cohort revealed a single association. Notably, the rs1080985 polymorphism on the CYP2D6 gene demonstrated an association across all analytical groupings, and two polymorphisms on SLCO1B3 occurred in complete linkage disequilibrium.
In contrast to the normal enzymatic findings, estimated glomerular filtration rates fell below the standard reference range of 90 to 120 milliliters per minute per 1.73 square meters across all cohorts. The mean estimated filtration rate was 65.20 plus or minus 16.97 milliliters per minute per 1.73 square meters in the comprehensive group, matching 63.96 plus or minus 15.92 milliliters per minute per 1.73 square meters in both individual prodrug cohorts, with a nonsignificant comparison p-value of 0.622. Although no significant variant associations emerged when analyzing either prodrug group individually, six variants associated significantly with filtration rate in the comprehensive grouping, three of which exhibited negative associations involving cytochrome P450 genes CYP2C19, CYP2C9, and CYP2D6.
The authors outlined multiple methodological constraints inherent to the pilot design, emphasizing that the limited sample size produced low frequency counts for certain alleles and restricted statistical resolution. Furthermore, the demographic composition remained predominantly non-Hispanic Caucasian males, precluding the assessment of polymorphisms that occur more frequently in other ancestries. Because the panel examined candidate loci rather than the full genome, additional relevant genetic determinants may have remained unassayed. Unmeasured background antiretroviral components, retrospective variability in laboratory monitoring intervals, and the absence of treatment-naive subjects further constrained causal inferences, leading the investigators to conclude that larger prospective studies incorporating pharmacokinetic profiling are necessary to validate these exploratory findings.
To contextualize these findings, the researchers highlighted key pharmacokinetic and physiological differences between the two nucleoside reverse transcriptase inhibitor prodrugs. Tenofovir disoproxil fumarate, introduced in 2001, exhibits low oral bioavailability because of poor intestinal stability and rapid efflux across the gastrointestinal tract. While effective as an antiretroviral component, it carries risks of renal toxicity and reductions in bone mineral density. In contrast, tenofovir alafenamide fumarate demonstrates greater stability, slower intracellular hydrolysis, and substantially higher plasma protein binding of approximately 80 percent compared to roughly 7 percent for tenofovir disoproxil fumarate. A standard 25-milligram dose of tenofovir alafenamide produces systemic active tenofovir diphosphate exposures nearly 90 percent lower than a 300-milligram dose of tenofovir disoproxil fumarate, while yielding higher intracellular concentrations in hepatocytes.
These distinct pharmacological behaviors also govern drug elimination pathways and cellular transport mechanisms. Glomerular filtration alongside active tubular secretion eliminates between 70 and 80 percent of tenofovir disoproxil fumarate into urine. Organic anion transporters OAT1 and OAT3 uptake tenofovir disoproxil fumarate into renal tubular cells, whereas multidrug resistance-associated protein 4 mediates efflux into the tubular lumen. In contrast, OAT1 and OAT3 do not participate in tubular influx of tenofovir alafenamide fumarate, of which less than 1 percent of intact drug is excreted in urine and roughly 30 percent in feces. Instead, polypeptide transporters OATP1B1 and OATP1B3 facilitate its uptake into hepatocytes. Because cytochrome P450 isoenzymes do not metabolize tenofovir, variations in membrane transport genes have previously been linked to elevated plasma levels and proximal tubulopathy.
In evaluating the modest clinical impact observed, the investigators underscored that normal average transaminase and blood urea nitrogen values suggest these specific genetic variations carried minimal immediate clinical harm within the cohort. Although mean estimated glomerular filtration rates fell below normal baseline thresholds across all participants, such depressions frequently occur among patients undergoing long-term antiretroviral regimens. The identified candidate variants, including the three cytochrome P450 associations linked to reduced glomerular filtration, warrant further clarification alongside broader clinical variables. Ultimately, the authors recommended expanding pharmacogenetic investigations to treatment-naive individuals and incorporating serial blood pharmacokinetic sampling stratified by genotype to elucidate whether targeted profiling can optimize prodrug selection in human immunodeficiency virus care.
Subject of Research: Pharmacogenetic associations between single nucleotide polymorphisms and clinical laboratory parameters during tenofovir therapy
Article Title: An Exploratory Pharmacogenetic Pilot Study of Two Reverse Transcriptase Inhibitors, Tenofovir Alafenamide Fumarate and Tenofovir Disoproxil Fumarate
Article References: Murrell, D. E., Kennard, B. C., Bertoni, M. E., Cluck, D. B., Moorman, J. P., Brown, S. D., Wang, K., Duffourc, M. M., & Harirforoosh, S. (2025). An Exploratory Pharmacogenetic Pilot Study of Two Reverse Transcriptase Inhibitors, Tenofovir Alafenamide Fumarate and Tenofovir Disoproxil Fumarate. Drugs in R&D, 25(2), 153-160. https://doi.org/10.1007/s40268-025-00509-6
Image Credits: AI Generated
DOI: 10.1007/s40268-025-00509-6
Keywords: Tenofovir alafenamide fumarate, Tenofovir disoproxil fumarate, Pharmacogenetics, Single nucleotide polymorphisms, HIV-1 antiretroviral therapy, Reverse transcriptase inhibitors, Alkaline phosphatase, Alanine aminotransferase, Aspartate aminotransferase, Blood urea nitrogen, Estimated glomerular filtration rate, VKORC1, ABCB1, CYP2D6, Linkage disequilibrium, Organic anion transporters, Renal tolerability, Hepatic biomarkers
News Source: Ophelia Keating. (November 13, 2026). Exploratory Pilot Study Evaluates Pharmacogenetic Links to Tenofovir Tolerability Markers. Scienmag.



